UBS Group
NGNE icon

UBS Group’s Neurogene NGNE Stock Holding History

UBS Group’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.74M Buy
185,679
+31,556
+20% +$611K ﹤0.01% 4373
2025
Q4 		$3.17M Sell
154,123
-73,593
-32% -$1.83M ﹤0.01% 4500
2025
Q3 		$3.95M Sell
227,716
-12,603
-5% -$253K ﹤0.01% 4283
2025
Q2 		$3.59M Buy
240,319
+31,603
+15% +$496K ﹤0.01% 4214
2025
Q1 		$2.44M Sell
208,716
-138,485
-40% -$2.41M ﹤0.01% 4534
2024
Q4 		$7.94M Buy
347,201
+342,077
+6,676% +$12.7M ﹤0.01% 3316
2024
Q3 		$215K Buy
5,124
+1,701
+50% +$66K ﹤0.01% 5821
2024
Q2 		$125K Sell
3,423
-6,295
-65% -$222K ﹤0.01% 6018
2024
Q1 		$495K Buy
9,718
+8,718
+872% +$291K ﹤0.01% 5216
2023
Q4 		$19.4K Buy
1,000
+942
+1,624% +$13.5K ﹤0.01% 7121
2023
Q3 		$912 Buy
58
+3
+5% +$44 ﹤0.01% 8224
2023
Q2 		$913 Sell
55
-690
-93% -$11.3K ﹤0.01% 8068
2023
Q1 		$10.4K Sell
745
-344
-32% -$4.03K ﹤0.01% 7579
2022
Q4 		$11.1K Buy
1,089
+364
+50% +$3.76K ﹤0.01% 8435
2022
Q3 		$10K Buy
725
+670
+1,218% +$13.7K ﹤0.01% 8440
2022
Q2 		$1K Hold
55
– – ﹤0.01% 9917
2022
Q1 		$2K Sell
55
-612
-92% -$35.7K ﹤0.01% 9653
2021
Q4 		$64K Buy
667
+460
+222% +$56K ﹤0.01% 6702
2021
Q3 		$30K Buy
207
+3
+1% +$459 ﹤0.01% 6754
2021
Q2 		$38K Sell
204
-1,656
-89% -$366K ﹤0.01% 6700
2021
Q1 		$458K Buy
1,860
+1,750
+1,591% +$447K ﹤0.01% 4939
2020
Q4 		$31K Sell
110
-163
-60% -$39.8K ﹤0.01% 6605
2020
Q3 		$66K Sell
273
-446
-62% -$108K ﹤0.01% 5451
2020
Q2 		$238K Buy
719
+395
+122% +$103K ﹤0.01% 4673
2020
Q1 		$74K Buy
324
+124
+62% +$25.5K ﹤0.01% 5527
2019
Q4 		$49K Sell
200
-53
-21% -$5.28K ﹤0.01% 6358
2019
Q3 		$14K Buy
253
+110
+77% +$6.71K ﹤0.01% 6951
2019
Q2 		$7K Buy
+143
New +$7.35K ﹤0.01% 7242
2019
Q1 		– Sell
-19
Closed -$1K – 8007
2018
Q4 		$1K Hold
19
– – ﹤0.01% 7905
2018
Q3 		$1K Sell
19
-161
-89% -$9.5K ﹤0.01% 7841
2018
Q2 		$9K Sell
180
-2,930
-94% -$764K ﹤0.01% 7194
2018
Q1 		$876K Buy
3,110
+2,760
+789% +$762K ﹤0.01% 3825
2017
Q4 		$82K Buy
350
+253
+261% +$59.3K ﹤0.01% 5495
2017
Q3 		$27K Buy
97
+14
+17% +$4.02K ﹤0.01% 6243
2017
Q2 		$23K Buy
+83
New +$23.8K ﹤0.01% 6192
2017
Q1 		– Sell
-25
Closed -$8K – 7853
2016
Q4 		$8K Hold
25
– – ﹤0.01% 7040
2016
Q3 		$7K Sell
25
-123
-83% -$24.8K ﹤0.01% 6987
2016
Q2 		$19K Buy
+148
New +$23.5K ﹤0.01% 6348
2016
Q1 		– Sell
-50
Closed -$13K – 7985
2015
Q4 		$13K Sell
50
-19
-28% -$5K ﹤0.01% 7128
2015
Q3 		$19K Sell
69
-889
-93% -$205K ﹤0.01% 6746
2015
Q2 		$133K Buy
958
+22
+2% +$3.35K ﹤0.01% 5187
2015
Q1 		$154K Buy
+936
New +$190K ﹤0.01% 5087

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

UBS Group's NGNE Position: Q1 2026 in Review

UBS Group increased its Neurogene (NGNE) stake by 20% in Q1 2026, buying an estimated $611K and bringing the position to 185,679 shares worth $3.74M. The position accounts for ﹤0.01% of the portfolio, ranked #4373.

UBS Group first reported a position in NGNE in Q1 2015 and has held it in 42 quarters since. The position peaked at $7.94M in Q4 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • UBS Group held 185,679 shares of Neurogene worth $3.74M as of Q1 2026.
  • UBS Group bought 31,556 Neurogene shares in Q1 2026, an estimated $611K.
  • Neurogene made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4373 holding.
  • UBS Group first reported a position in Neurogene in Q1 2015 and has held it in 42 quarters since.
  • UBS Group's Neurogene position peaked at $7.94M in Q4 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.